← All trials
NCT05497635
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2022
- Primary completion
- Mar 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Aug 11, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 26
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Staidson (Beijing) Biopharmaceuticals Co., LtdLead sponsor
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.